Are the New GLP-1 Pills as Effective as Ozempic? An Obesity Doctor Explains 

Most people I know have an opinion about GLP-1 medications. Fewer have accurate information. I sat down with Dr. Jessica Duncan, Chief Medical Officer at Ivim Health and a board-certified obesity medicine physician, to ask the questions worth actually asking. 

Start from the beginning for anyone still fuzzy. What is a GLP-1, and how does it work? 

GLP-1 stands for glucagon-like peptide-1, a hormone your body already makes naturally. It signals to your brain that you’re full, slows digestion, and helps regulate blood sugar. GLP-1 medications mimic that signal. What they do is reduce appetite and quiet what patients call food noise, that persistent mental pull toward eating that people with obesity describe as exhausting. 

I also want to say this plainly: obesity is a chronic disease with real biological drivers. Hormonal, genetic, metabolic. It is not a willpower problem. GLP-1 medications treat the underlying biology. That’s why they work when so many other approaches haven’t. 

Most people I know say “Ozempic” and mean any GLP-1. Can you map the actual landscape? 

Ozempic has become like Kleenex. But Ozempic is one product, FDA-approved for type 2 diabetes, not weight loss. Wegovy is the same molecule, semaglutide, approved for chronic weight management. Then there’s a second category: tirzepatide. Mounjaro for diabetes, Zepbound for weight loss. 

So the real choice is between two molecules. Semaglutide targets one receptor. Tirzepatide targets two, GLP-1 and GIP, which is why it’s called a dual agonist. Clinical trials have generally shown higher average weight loss with tirzepatide. But higher average doesn’t mean right for every patient. Your health history, side effect tolerance, cost, insurance coverage, all of it matters. The right medication is the one prescribed by someone who actually knows your situation. 

There are now oral versions of GLP-1s. Are they as effective as the injections? 

The appeal is obvious. No needles, daily routine. But oral and injectable are not equivalent. Injectable GLP-1s go directly into the bloodstream. Oral formulations have to survive digestion, and the bioavailability is lower. Injectable semaglutide has consistently shown stronger outcomes than oral in the published literature.  

If the administration of an injection is preventing someone from starting obesity treatment, a pill is likely better than not starting at all. But that tradeoff should be discussed before someone chooses, not three months inwhen results aren’t what they expected. 

People talk a lot about “Ozempic body,” losing muscle along with fat. Is the medication causing that? 

The risk is real. The diagnosis is wrong. 

Muscle loss is a side effect of weight loss, not GLP-1s. It always has been. We just didn’t talk about it much when people were losing five or ten pounds. GLP-1s changed the scale of loss, so the muscle loss became visible and the drug got blamed. 

What I’d push back on is the idea that it’s inevitable. The patients I see who protect their lean mass are doing specific things. They’re losing weight at a controlled pace instead of racing to the lowest number. They’restrength training, not just cardio. They’re prioritizing protein. They’re sleeping enough for their bodies to actually rebuild muscle. Most patients don’t arrive knowing that sleep matters as much as diet, or that the cardio routines many women default to can accelerate muscle loss. That’s what a clinical team teaches. When someone loses muscle they shouldn’t have, it’s usually because no one was paying attention. That’s a care failure, not a drug failure. 

A lot of people feel embarrassed about being on a GLP-1, like they cheated somehow. Where does that come from? 

The same place the willpower myth comes from. We’ve spent decades telling people weight is a personal failing, so even when we hand them something that works, they feel guilty for using it. 

People don’t feel shame about medication for high blood pressure. Obesity belongs in the same category. The biology is just as real. And the injection is often the easiest part of this. The harder work is everything around it: nutrition, habits, honest conversations with your care team. Nobody coasts through that. 

The fear I hear most is being on this forever. How do you help patients think about that? 

Some people should be on it long term. Obesity is a chronic disease, and for many patients ongoing medication is appropriate management, the same way someone with hypertension stays on blood pressure medication indefinitely. Stopping doesn’t make the disease go away. Weight regain after discontinuation isn’t a personal failure. It’s a predictable biological outcome. And for some with specific risk factors, lifelong GLP-1 therapy is the best plan.  

But some patients, with the right lifestyle foundation built during treatment, can reduce or discontinue over time. What separates those paths is almost entirely what you do while you’re on it. The medication gives you a real window. What you build in it is what lasts. 

For someone still on the fence. What do you tell them? 

You don’t have to figure it out alone. There’s no shortage of information about GLP-1s. Some of it is good. A lot of it is incomplete, or written about someone whose situation is nothing like yours. The right medication, the right dose, the right timeline. These aren’t decisions that should be made based on what you read in an article, including this one. 

Find a provider who will give you a real evaluation. Ask how they manage dosing. Ask what happens between your visits. If the answer is essentially nothing, you fill your prescription and go it alone, that tells you a lot about what you’re actually signing up for. The medication is one piece of this. The structure around it is what drives outcomes.  

Dr. Jessica Duncan is the Chief Medical Officer at Ivim Health and a board-certified obesity medicine physician. Her peer-reviewed research on GLP-1 outcomes is published in Obesity Pillars.